BioMarin Pharmaceutical Inc.
GB ˙ LSE ˙ US09061G1013
54,65 $ ↑0,60 (1,11%)
2026-06-03
AKTIENPREIS
SecurityGB:0HNC / BioMarin Pharmaceutical Inc.
InstitutionKBC Group NV
Latest Disclosed Ownership127,194 shares
Latest Disclosed Value $ 7,185
KBC Group NV reports 24.64% decrease in ownership of 0HNC / BioMarin Pharmaceutical Inc.

On May 7, 2026 - KBC Group NV filed a 13F-HR form disclosing ownership of 127,194 shares of BioMarin Pharmaceutical Inc. (GB:0HNC) valued at $7,084,706 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 26, 2026 disclosing 168,779 shares of BioMarin Pharmaceutical Inc.. This represents a change in shares of -24.64% during the quarter. The current value of the position is $6,951,152 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 127,194 -41,585 -24.64 7 -30.00 0.0180
2026-01-26 2025-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 168,779 15,362 10.01 10 25.00 0.0229
2026-01-20 2025-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 153,417 27,000 21.36 8 33.33 0.0199
2025-08-08 2025-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 126,417 1,117 0.89 7 -25.00 0.0188
2025-04-25 2025-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 125,300 -5,398 -4.13 9 0.00 0.0275
2025-01-22 2024-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 130,698 -33,249 -20.28 9 -27.27 0.0237
2024-11-06 2024-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 163,947 -68,308 -29.41 12 -42.11 0.0348
2024-07-17 2024-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 232,255 2,264 0.98 19 -5.00 0.0578
2024-05-08 2024-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 229,991 -12,109 -5.00 20 -13.04 0.0638
2024-02-13 2023-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 242,100 -7,922 -3.17 23 4.55 0.0828
2024-02-15 2023-09-30 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 250,022 -37,208 -12.95 22 -8.33 0.0903
2023-11-22 2023-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 284,901 0 25 0.1028
2024-02-15 2023-06-30 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 287,230 7,566 2.71 25 -11.11 0.1024
2023-07-28 2023-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 284,901 6,723 25 0.1028
2024-02-14 2023-03-31 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 279,664 -42,036 -13.07 27 -18.18 0.1154
2023-05-04 2023-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 278,178 51,215 27 0.1274
2024-02-14 2022-12-31 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 321,700 94,560 41.63 33 73.68 0.1615
2023-02-13 2022-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 226,963 -177 19 0.0001
2024-02-15 2022-09-30 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 227,140 -700 -0.31 19 5.56 0.1001
2022-11-08 2022-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 226,963 -877 19,240 0.1006
2024-02-14 2022-06-30 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 227,840 43,486 23.59 19 28.57 0.0942
2022-07-26 2022-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 227,840 43,486 18,881 0.0950
2024-02-14 2022-03-31 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 184,354 -8,151 -4.23 14 -17.65 0.0562
2022-05-06 2022-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 184,354 -8,151 14,214 0.0525
2024-02-14 2021-12-31 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 192,505 -135,059 -41.23 17 -99.93 0.0561
2022-02-03 2021-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 192,505 -135,059 17,008 0.0533
2021-11-10 2021-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 327,564 93,826 40.14 25,317 29.81 0.0928
2022-02-15 2021-06-30 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 233,738 49,110 26.60 19,503 39.90 0.0703
2021-08-11 2021-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 233,738 49,110 19,503 0.0703
2022-02-14 2021-03-31 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 184,628 40,507 28.11 13,941 -88.97 0.0565
2021-04-26 2021-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 184,628 40,507 13,941 0.0565
2022-02-14 2020-12-31 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 144,121 -56,718 -28.24 126,380 727.09 0.0595
2021-02-10 2020-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 144,121 -56,718 12,638 0.0582
2022-02-14 2020-09-30 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 200,839 10,052 5.27 15,280 -35.07 0.0900
2020-10-28 2020-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 200,839 10,052 15,280 0.0904
2022-02-14 2020-06-30 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 190,787 93,483 96.07 23,532 186.17 0.1555
2020-08-10 2020-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 190,787 93,483 23,532 0.1575
2020-05-04 2020-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 97,304 -62,427 -39.08 8,223 -39.11 0.0688
2020-02-11 2019-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 159,731 12,695 8.63 13,505 36.28 0.0854
2019-11-07 2019-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 147,036 27,083 22.58 9,910 -3.54 0.0727
2019-08-08 2019-06-30 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 119,953 16,852 16.35 10,274 12.17 0.0795
2019-07-30 2019-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 119,953 -18,954 10,274
2019-08-07 2019-03-31 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 103,101 -4,402 -4.09 9,159 0.05 0.0755
2019-05-10 2019-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 103,101 -4,402 9,159
2019-01-31 2018-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 107,503 -34,780 -24.44 9,154 -33.66 0.1020
2018-11-14 2018-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 142,283 101,089 245.40 13,798 255.53 0.1044
2018-08-03 2018-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 41,194 -233,204 -84.99 3,881 -82.55 0.0338
2018-08-03 2018-03-31 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 274,398 -39,873 -12.69 22,246 -20.62 0.2058
2018-05-09 2018-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 274,398 -39,873 22,246
2018-08-03 2017-12-31 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 314,271 -52,601 -14.34 28,023 -17.93 0.2396
2018-02-07 2017-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 314,271 -52,601 28,023
2017-11-13 2017-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 366,872 29,264 8.67 34,145 11.36 0.3099
2017-08-04 2017-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 337,608 52,847 18.56 30,662 22.67 0.2963
2017-05-10 2017-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 284,761 109,033 62.05 24,996 71.70 0.2256
2017-02-16 2016-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 175,728 88,857 102.29 14,558 81.14 0.1443
2016-11-03 2016-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 86,871 45,963 112.36 8,037 152.50 0.0949
2016-08-03 2016-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 40,908 2,046 5.26 3,183 -0.69 0.0455
2016-05-11 2016-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 38,862 19,407 99.75 3,205 57.26 0.0532
2016-02-11 2015-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 19,455 -9,749 -33.38 2,038 -33.75 0.0375
2015-11-12 2015-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 29,204 -47,215 -61.78 3,076 -70.57 0.0619
2015-12-16 2015-06-30 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 76,419 19,865 35.13 10,453 48.31 0.1344
2015-07-31 2015-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 76,419 10,453
2015-12-16 2015-03-31 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 56,554 10,473 22.73 7,048 69.22 0.0895
2015-04-30 2015-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 56,554 7,048
2015-12-15 2014-12-31 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 46,081 38,977 548.66 4,165 713.48 0.0496
2015-02-12 2014-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 46,081 4,165
2014-10-16 2014-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 7,104 -5,282 -42.64 512 -33.59 0.0179
2014-08-01 2014-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 12,386 -35,221 -73.98 771 -76.26 0.0088
2014-04-30 2014-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 47,607 -46,026 -49.16 3,247 -50.71 0.0513
2014-01-21 2013-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 93,633 23,388 33.29 6,587 29.92 0.0996
2013-11-06 2013-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 70,245 11,349 19.27 5,070 54.43 0.0816
2013-07-29 2013-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 58,896 58,896 3,283 0.0609
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.